Biopharmaceutical company developing treatments for gastrointestinal diseases.
Phathom Pharmaceuticals, Inc., headquartered in Florham Park, New Jersey, is a clinical-stage biopharmaceutical company specializing in the development and commercialization of innovative treatments for gastrointestinal (GI) diseases. Founded in 2018, Phathom Pharmaceuticals focuses on addressing critical medical needs through its advanced pipeline of therapeutic solutions.
Central to Phathom's portfolio is vonoprazan, a potassium-competitive acid blocker (P-CAB) designed to inhibit acid secretion in the stomach. The company holds exclusive rights to vonoprazan in the United States, Europe, and Canada. Currently, vonoprazan is undergoing Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), a common and often debilitating GI condition.
In addition to its application for GERD, Phathom Pharmaceuticals is exploring vonoprazan's potential in combination with antibiotics for the treatment of Helicobacter pylori infection, a prevalent bacterial infection linked to gastric ulcers and other GI complications. The company's strategic focus on these therapeutic areas underscores its commitment to advancing treatments that improve patient outcomes and quality of life.
With a dedicated team of researchers and clinicians, Phathom Pharmaceuticals continues to leverage its expertise in GI disorders to drive innovation and expand its impact in the field of gastroenterology. By harnessing cutting-edge research and development efforts, the company aims to address unmet medical needs and deliver transformative therapies to patients worldwide.